Major Depressive Disorder

Current polygenic risk scores for depression were not more likely to be linked to major depressive disorder than were other known risk factors, according to results of a case-cohort study published in JAMA Psychiatry.

Sequential integration of psychotherapy following response to acute-phase pharmacotherapy was associated with a reduced risk for relapse in patients with major depressive disorder, according to study results published in JAMA Psychiatry.

Adjunctive pimavanserin was associated with significant improvements in dysregulated sleep among individuals with major depressive disorder, according to study results published in Journal of Clinical Psychiatry.

Neighborhood-level armed violence appeared associated with increased risk for major depressive disorder among children, according to study results published in JAMA Network Open.

Prescription opioid use appeared to increase risk for depression, according to results of a mendelian randomization analysis published in JAMA Psychiatry.

Psychiatric disorders were common among cardiac outpatients in the Middle East, according to results of a cross-sectional study published in Psychiatric Annals.

Anhedonia severity differed across various disorders, according to results of a systematic review and meta-analysis published in JAMA Network Open.

Magnetic seizure therapy appeared to decrease suicidality among patients with treatment-resistant depression, according to results of a nonrandomized controlled trial published in JAMA Network Open.

Ketamine dose and blood level appeared closely related, and both were significantly associated with antidepressant benefit, according to results of a randomized clinical trial published in JAMA Network Open.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced FDA approval of a supplemental new drug application for Spravato CIII nasal spray for the rapid reduction of depressive symptoms.